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Purpose. Screening has been shown to lower the morbidity and mortality for breast, cervical, and colorectal
cancers. Despite the availability of cancer screening, nearly 70,000 women die each year from these cancers.
We conducted a study in 2008 within a privately-insured patient population of women who were members of
an integrated health care system in Southeastern Michigan, for whom information on ovarian cancer risk as
well as personal and family history of cancer was available. Methods. We used a population-based, weighted
stratiﬁed random sample of women from a single health care institution to assess the proportion with up-to-
date breast, cervical, and colorectal screening. Multivariable analyses were conducted to identify predictors of
screening behavior. Results. In our study, women reported cervical and breast cancer screening above 90% and
colorectal cancer screening above 75%. Conclusions. The results of our study hold promise that Healthy People
2020 cancer screening objectives might be obtainable as access to health insurance is expanded among US
residents.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Screening has been shown to lower morbidity and mortality for
breast cancer, cervical cancer, and colorectal cancer (CRC) (Zappa
et al., 1997; Laara et al., 1987; IARC Working Group, 1986; van der
Graaf et al., 1988; Mook et al., 2011). Despite cancer screening, nearly
70,000 women die yearly from these cancers (Jemal et al., 2013).
Healthy People 2020 objectives aim to have 81% of the eligible popula-
tion screened for breast cancer with mammography, 93% for cervical
cancer, and 70% for CRC (Healthy People 2020, 2013). However, results
from the 2010 US National Health Interview Survey recently showed
that overall screening rates are well below Healthy People 2020 targets
(Coleman King et al., 2012; Smith et al., 2011). Several studies have
shown strong associations between health insurance coverage and up-
take of cancer screening services (Farkas et al., 2012; Fedewa et al.,
2012; Carney et al., 2012; Akinyemiju et al., 2012; Zhao et al., 2011;
Palmer et al., 2011; Shires et al., 2011), recent changes in the US health
care system might address this major barrier of access to care.
As opportunities for health care coverage in the US increase, addi-
tional factorsmight continue to pose barriers to cancer screening. Previ-
ous studies of cancer screening have highlighted disparities associated
with race, ethnicity, income, education, and other socio-economicss article under the CC BY-NC-ND licefactors (Smith et al., 2011; Shires et al., 2011; Klabune et al., 2013; U.S.
Preventive Services Task Force, 2002; Swan et al., 2010;
Courtney-Long et al., 2011; Miller et al., 2012; Shapiro et al., 2012;
Joseph et al., 2012; Rauscher et al., 2012; Berry et al., 2009). In addition,
several studies have also found that family history of cancer has been as-
sociated with uptake of cancer screening (Townsend et al., 2013; Zlot
et al., 2012; Vyas et al., 2012; Meissner et al., 2007). As more individuals
enter the health insurance market, having a greater understanding of
the barriers to cancer screening uptake among insured populations
will facilitate more focused strategies and interventions to reach
Healthy People 2020 objectives.
We conducted a studywithin a privately-insured patient population
of women who were members of an integrated health care system in
Southeastern Michigan. Our sampling method permitted population-
based estimates of reported breast, cervical, and CRC screening.
Methods
Study population
We used baseline data from a Centers for Disease Control and Pre-
vention (CDC) study evaluating cancer risk perception and ovarian can-
cer screening among women within the Henry Ford Health System
(HFHS). Eligible women were 30 years of age or older, had no previous
diagnosis of ovarian cancer, and had not undergone bilateralnse (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Demographics of study population, women, aged 30 or older, Henry Ford Health System,
2008.
Characteristic n (%)
Total study population 2524 (100%)
Age group (n = 2524)
30–39 227 (9.0)
40–49 542 (21.5)
50–59 837 (33.2)
60–69 641 (25.4)
70 or older 277 (11.0)
Race/ethnicity (n = 2507)
Non-Hispanic White 1659 (66.2)
Non-Hispanic Black 691 (27.6)
Othera 157 (6.3)
Marital status (n = 2523)
Married/partnered 1692 (67.0)
Separated/divorced 380 (15.1)
Single 231 (9.2)
Widowed 219 (8.7)
Education (n = 2523)
bHigh school 89 (3.5)
High school/GED 687 (27.2)
College, b4 years 830 (32.9)
College, ≥4 years 484 (19.2)
Graduate degree 433 (17.2)
Incomeb (n = 2523)
b$25,000 263 (10.4)
$25,000–b$50,000 706 (28.0)
$50,000–b$75,000 592 (23.5)
$75,000 or more 962 (38.1)
Abbreviation: GED, general educational development (high school equivalency).
a “Other” includes Latina, non-Hispanic multiracial, and non-Hispanic of “other” or un-
speciﬁed race.
b Refused or unknown income was imputed with hot-deck imputation procedures.
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ovarian cancer is very low. HFHS provided a list of 55,887 potential eli-
gible patients and their contact information. The survey was conducted
in two phases—an eligibility screener and the full interview. The eligibil-
ity screener consisted of a ﬁve-minute series of questions on personal
history of breast or ovarian cancer, bilateral oophorectomy, and breast
and ovarian cancers among ﬁrst- and second-degree relatives. Based
on this screener, womenwere classiﬁed into ovarian cancer risk groups
(average, elevated, and high) for stratiﬁed random sampling purposes,
insuring sufﬁciently-powered subsamples from each risk group, includ-
ing an oversample ofwomen at high risk. Between January 16, 2008 and
December 13, 2008 the programmed computer-assisted telephone
interview (CATI) system randomly selected eligible respondents for
participation in a full interview (Leadbetter et al., 2013). Approval for
the study was obtained from the Institutional Review Boards (IRBs) of
the CDC and the HFHS. All respondents provided informed consent
before we conducted interviews.
Outcome measures
Respondents were asked if they had ever had a mammography or a
Pap test and when they had their most recent exam. Women who
reported having had a mammogram in the past two years or a Pap
test in the past 3 years were classiﬁed as compliant with screening
guidelines for a mammography or Pap test, respectively (Smith et al.,
2011; Shires et al., 2011; U.S. Preventive Services Task Force (USPSTF),
2011). Respondents were asked if they had ever heard of or had a
fecal occult blood test (FOBT), a colonoscopy or a sigmoidoscopy, and
when they had their most recent exam. We classiﬁed respondents
who reported having had a colonoscopy in the past 10 years, a sigmoid-
oscopy in the past 5 years, or an FOBT in the past year as having had a
CRC test within recommended screening guidelines (Smith et al.,
2011; U.S. Preventive Services Task Force (USPSTF), 2011). For the anal-
yses of mammography, we included women ≥40 years of age because
during the study period the USPSTF recommended ages for screening
included women aged 40–49 (U.S. Preventive Services Task Force,
2002). Women ≥30 years of age and without a hysterectomy were in-
cluded in the Pap test analyses as the youngest women in our sample
were age 30; CRC testing analyses included women ≥50 years of age
(Smith et al., 2011; U.S. Preventive Services Task Force (USPSTF),
2011). No upper age limit was imposed in these analyses.
Covariates
Using the detailed family cancer history from the baseline survey,
we deﬁned an indicator for any breast cancer, cervical cancer or CRC
history in the family and used the respondent's personal cancer history
information to determine cancer survivorship status. We included age,
race/ethnicity, marital status, education, and income. Missing income
data were imputed using hot-deck imputation.
Statistical analyses
Prevalence estimates of up-to-date mammography, Pap testing, and
CRC testing used responses weighted to reﬂect selection probabilities
based on the risk group-speciﬁc sampling rates and also to adjust for
non-response. We conducted a bivariate analysis of these prevalence
estimates by demographics and by various cancer history covariates,
testing for general associations with chi-square statistics. Multivariable
logistic regression models for each screening test were used to deter-
mine the fully-adjusted associations between each outcome and the de-
mographic variables, and between each outcome and the cancer history
variables. For each logistic model, these covariate associations were
determined by Wald F-test statistics; potential effect modiﬁcation and
model lack-of-ﬁt were also assessed. We deﬁned the referent level for
each covariate as the category with the smallest cancer testingprevalence estimate from the bivariate analysis. Adjusted testing per-
centages or predicted marginals (PMs) were derived for each category
of the model covariates. Rate ratios (RRs) were calculated as the PM of
each non-referent category relative to the PM of the referent category
for each covariate, with 95% conﬁdence intervals (CIs). All statistical
analyses were performed using SAS 9.2 with SUDAAN (Research Triangle
Institute, Research Triangle Park, NC) to calculate appropriate standard
errors for the stratiﬁed sample design. We considered any test with a
p-value ≤ 0.05 to be statistically signiﬁcant.
Results
Of 55,887 women in the master list of patients, 20,483 (36.7%)
underwent eligibility screening and 16,720 (81.6%) were determined
to be eligible for the study. A total of 3307 women were invited to par-
ticipate in the study and 2524 womenwere successfully consented and
interviewed (overall response rate 76.3%) (Leadbetter et al., 2013).
Table 1 provides sample sizes and unweighted percentages correspond-
ing to the demographic distributions of the participating women.
Bivariate analysis
Table 2a presents the prevalence rates for mammography, Pap test,
and CRC testing overall and by demographics. Overall, 91.0% of partici-
pants aged ≥40 (n = 2297) had a mammography within the past two
years, 91.3% of participants aged ≥30 and who did not have a hysterec-
tomy (n=2152) had a Pap testwithin the past three years, and 78.7% of
participants aged ≥50 (n = 1755) were compliant with CRC testing.
For mammography, women aged 50–69 were more likely to report
having had a screening test than women aged 40–49 (p = 0.0004)
and aged ≥70 (p b 0.0001). For Pap tests, women aged 30–69 were
more likely to report being tested compared to those aged ≥70 (p b
Table 2a
Prevalence of mammography, Pap test, and colorectal cancer testing compliance by
demographics, women of eligible screening agea, Henry Ford Health System, 2008.
Characteristic Mammography Pap test CRC testb
(n = 2297) (n = 2152) (n = 1755)
% (95% CI) % (95% CI) % (95% CI)
Overall 91.0 (89.4–92.4) 91.3 (89.7–92.6) 78.7 (76.1–81.0)
Age group (P-values) .0002 .0006 b .0001
30–39 NA 89.2 (83.7–93.0) NA
40–49 86.8 (82.9–89.9) 92.0 (88.6–94.4) NA
50–59 92.9 (90.4–94.8) 93.4 (90.6–95.4) 71.7 (67.7–75.4)
60–69 94.8 (92.2–96.5) 94.0 (91.2–96.0) 86.9 (83.2–89.9)
70 or older 86.4 (80.2–90.9) 76.6 (68.3–83.3) 81.6 (74.8–86.8)
Race/ethnicity
(P-values)
.916 .046 .010
Non-Hispanic
White
90.9 (88.9–92.5) 92.7 (90.8–94.2) 77.4 (74.3–80.3)
Non-Hispanic Black 91.6 (88.4–93.9) 88.2 (84.5–91.1) 84.1 (79.4–88.0)
Otherc 91.4 (83.5–95.7) 89.6 (82.0–94.3) 68.4 (55.2–79.2)
Marital status
(P-values)
.009 .0503 .119
Married/partnered 92.9 (91.1–94.3) 92.7 (90.8–94.2) 80.2 (77.1–82.9)
Separated/divorced 87.4 (82.2–91.2) 90.0 (85.1–93.4) 74.0 (66.9–80.0)
Single 83.8 (76.1–89.4) 84.4 (77.6–89.5) 70.3 (58.8–79.6)
Widowed 89.9 (83.2–94.2) 90.7 (84.1–94.7) 81.3 (73.7–87.2)
Education (P-values) .010 b .0001 .491
bHigh school 94.9 (85.1–98.4) 78.2 (62.2–88.7) 76.5 (61.8–86.8)
High school/GED 90.5 (87.1–93.0) 86.4 (82.3–89.7) 80.2 (75.4–84.2)
College, b4 years 88.2 (85.1–90.8) 92.4 (89.9–94.3) 77.9 (73.4–81.9)
College, ≥4 years 92.4 (88.6–95.0) 91.9 (88.0–94.6) 74.7 (67.7–80.6)
Graduate degree 95.0 (91.6–97.0) 96.6 (93.6–98.3) 81.9 (75.8–86.7)
Income (P-values) .048 b .0001 .278
b$25,000 89.7 (84.0–93.6) 81.0 (73.5–86.8) 81.0 (73.9–86.5)
$25,000–b$50,000 88.0 (84.4–90.8) 86.5 (82.6–90.0) 81.5 (76.9–85.3)
$50,000–b$75,000 91.5 (88.0–94.1) 93.0 (89.7–95.3) 75.6 (69.8–80.6)
$75,000 or more 93.2 (90.9–95.0) 95.5 (93.4–96.9) 77.2 (72.7–81.2)
NA:Not applicable. Indicated age groups not included in the analysis domain ofmammog-
raphy or CRC screening test outcomes.
Signiﬁcant ﬁndings are determined by P-values ≤ 0.05 and are displayed in bold.
a Eligible screening ages are 40 years or older for mammography, 30 years or older for
Pap test, and 50 years or older for colorectal cancer (CRC) test.
b CRC test compliance includes colonoscopy in the past 10 years, sigmoidoscopy in the
past 5 years, or fecal occult blood test within 1 year.
c “Other” includes Latina, non-Hispanic multiracial, and non-Hispanic of “other” or
unspeciﬁed race.
Table 2b
Prevalence of mammography, Pap test, and colorectal cancer testing compliance by
personal and family cancer history, women of eligible screening agea, Henry Ford Health
System, 2008.
Characteristic Mammography Pap test bCRC test
(n = 2297) (n = 2152) (n = 1755)
% (95% CI) % (95% CI) % (95% CI)
Cancer survivor
(P-values)
0.827 0.422 0.004
Yes 90.7 (87.0–93.4) 92.6 (88.8–95.1) 85.1 (80.4–88.9)
No 91.1 (89.3–92.6) 91.1 (89.4–92.6) 77.6 (74.7–80.2)
Any cancer family Hx
(p-values)
0.989 0.007 0.796
Yes 91.0 (89.3–92.5) 92.7 (91.1–94.0) 78.9 (76.1–81.4)
No 91.0 (86.9–93.9) 86.6 (81.9–90.2) 78.0 (71.4–83.4)
Breast ca. family Hx
(P-values)
0.256 – –
Yes 92.1 (90.2–93.7) NA NA
No 90.6 (88.6–92.4) NA NA
Cervical ca. family Hx
(P-values)
– 0.648 –
Yes NA 93.2 (78.8–98.0) NA
No NA 91.2 (89.6–92.6) NA
CRC ca. family Hx
(P-values)
– – 0.003
Yes NA NA 85.8 (80.0–90.1)
No NA NA 77.2 (74.3–79.8)
NA: Not applicable. Each cancer type-speciﬁc family history covariate was assessed for
only one outcome: breast cancer for mammography, cervical cancer for Pap test, and
colorectal cancer for CRC testing.
Signiﬁcant ﬁndings are determined by P-values ≤ 0.05 and are displayed in bold.
a Eligible screening ages are 40 years or older for mammography, 30 years or older for
Pap test, and 50 years or older for colorectal cancer (CRC) test.
b CRC test compliance includes colonoscopy in the past 10 years, sigmoidoscopy in the
past 5 years, or FOBT within the past year.
Table 3a
Mammography screening compliance predicted marginal rate ratio with 95% conﬁdence
interval, women, aged 40 or older, Henry Ford Health System, 2008.
Model effects — demographics only Rate ratio (95% CI)
Age group (p-value b 0.001)
40–49 0.99 (0.91–1.07)
50–59 1.06 (0.99–1.14)
60–69 1.08 (1.01–1.16)
70 or older Referent
Marital status (p-value = 0.005)
Single Referent
Married/partnered 1.09 (1.01–1.17)
Separated/divorced 1.02 (0.93–1.11)
Widowed 1.06 (0.96–1.17)
Education (p-value = 0.035)
College, b4 years Referent
bHigh school 1.08 (1.01–1.15)
High school graduate/GED 1.02 (0.98–1.07)
College, ≥4 years 1.05 (1.00–1.10)
Graduate degree 1.07 (1.03–1.12)
Table 3a displays only signiﬁcant associations, as determined by P-values ≤ 0.05.
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to have reported a test than women aged 50–59 (p b 0.0001). Marital
status was signiﬁcantly associated with mammography (p = 0.009)
and marginally associated with Pap test (p = 0.0503); married or
partnered women consistently had the highest observed rates across
all three outcomes, while single or never married women had the
lowest observed rates. Mammography was signiﬁcantly associated
with education (p = 0.010) and income (p = 0.048), as was Pap test
(both p b 0.0001). For both outcomes, observed test proportions were
highest among those with graduate degrees and those with annual
household incomes of $75,000 or more.
Table 2b presents the proportions tested for mammography, Pap
test, and CRC testing outcomes by several cancer history variables.
Neither cancer survivorship status nor family cancer history status
was associated with mammography screening compliance. However,
having a Pap test was signiﬁcantly associated with any family cancer
history status (p = 0.007). Among women with any family cancer his-
tory, the Pap test proportion was 92.7% compared to 86.6% among
those women without any family cancer history. Having a CRC test
was signiﬁcantly associated with CRC family history (p = 0.003), with
an 85.8% test proportion among those with a CRC family history com-
pared to 77.2% among those without. CRC testing was also signiﬁcantly
associatedwith personal cancer survivorship (p=0.004), with 85.1% ofcancer survivors tested compared to 77.6% among those who had not
had cancer.
Multivariable logistic regression models
Tables 3a, 3b, and 3c provide the multivariable logistic regression
modeling results for the mammography, Pap test, and CRC test out-
comes, respectively. All three outcomes were characterized by main
effects-only models as no signiﬁcant effect modiﬁers were detected.
The mammography model included three demographic effects: age
group, marital status, and education. Mammography screening was 8%
higher in the 60–69 age group compared to the 70 or older age group,
Table 3b
Pap test compliance predicted marginal rate ratio with 95% conﬁdence interval, women,
aged 30 or older, Henry Ford Health System, 2008.
Model effects Rate ratio (95% CI)
Cancer history
Any family cancer history (p-value = 0.004)
No Referent
Yes 1.06 (1.01–1.10)
Demographics
Age group (p-value b 0.001)
30–39 1.08 (0.98–1.19)
40–49 1.12 (1.02–1.22)
50–59 1.14 (1.04–1.24)
60–69 1.15 (1.06–1.25)
70 or older Referent
Education (p-value = 0.003)
bHigh school Referent
High school graduate/GED 1.05 (0.91–1.21)
College, b4 years 1.11 (0.96–1.28)
College, ≥4 years 1.09 (0.94–1.27)
Graduate degree 1.16 (1.00–1.34)
Table 3b displays only signiﬁcant associations, as determined by P-values ≤ 0.05.
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mogram than single women.Womenwith at least 4 years of college ed-
ucation or less than a high school educationwere 5% and 8%more likely
to have amammogram, respectively, thanwomenwith less than 4 years
of college. Pap test screening effects included having any family cancer
history (a 6% increase in Pap test screening compared to those without
a family cancer history). Women aged 40–49, 50–59, and 60–69 were
12%, 14%, and 15%, respectively, more likely to have a Pap test than
women ages 70 or older, while women with graduate degrees were
16% more likely to have a Pap test than women with less than a high
school education. CRC screening test effects included having a CRC fam-
ily history, which increased the likelihood of having a CRC test by 11%,
while women who were cancer survivors had a 9% increased rate of
CRC testing. Demographically, women aged 60 and older were more
likely to have a CRC test than women aged 50–59, while non-HispanicTable 3c
Colorectal cancer test compliance associations predicted marginal rate ratio with 95%
conﬁdence interval, women, aged 50 or older, Henry Ford Health System, 2008.
Model effects Rate ratio (95% CI)
Cancer history
Colorectal cancer family history (p-value = 0.010)
None Referent
Any 1.11 (1.04–1.19)
Cancer survivor (p-value = 0.016)
No Referent
Yes 1.09 (1.02–1.16)
Demographics
Age group (p-value b 0.0001)
50–59 Referent
60–69 1.21 (1.13–1.29)
70 or older 1.16 (1.05–1.27)
Race/ethnicity (p-value = 0.001)
Othera Referent
Non-Hispanic White 1.15 (0.96–1.37)
Non-Hispanic Black 1.29 (1.08–1.54)
Marital status (p-value = 0.028)
Single Referent
Married/partnered 1.16 (0.99–1.36)
Separated/divorced 1.04 (0.87–1.25)
Widowed 1.10 (0.91–1.33)
Table 3c displays only signiﬁcant associations, as determined by P-values ≤ 0.05.
a “Other” includes Latina, non-Hispanic multiracial, and non-Hispanic of “other” or
unspeciﬁed race.Black women were 29%more likely to have a CRC test than a combined
race/ethnicity group of Hispanics and all non-Hispanic White women.
Discussion
Our results indicate that rates for mammography, Pap testing, and
CRC testing are higher within our insured population compared to na-
tional estimates (91.0% vs. 72.4% for mammography, 91.3% vs. 83.0% for
Pap testing, and 78.7% vs. 58.6% for CRC screening) (Coleman King
et al., 2012). Similar to cancer screening studies at a national level, we
also found that older age, greater education, being married or partnered,
and having a higher income were associated with mammography
screening (Coleman King et al., 2012; Swan et al., 2010; Courtney-Long
et al., 2011; Miller et al., 2012). Contrary to some previous studies, we
found no differences in mammography screening uptake based on racial
or ethnic groups (Coleman King et al., 2012; Swan et al., 2010;
Courtney-Long et al., 2011;Miller et al., 2012). Studies assessing Pap test-
ing have found that screening rates increase with age (until age 65–70),
greater educational attainment, and income (Coleman King et al., 2012;
Swan et al., 2010). Among our population, Black women had a lower
screening rate than White women, whereas in other studies Black
(Coleman King et al., 2012) and Hispanic women (Swan et al., 2010) re-
ported greater adherence to Pap test screening.
A recent publication of CRC screening in a nationally representative
sample similarly found that a higher percentage of those aged 60–69
and aged ≥70 were compliant with CRC screening guidelines than
those aged 50–59 (Shapiro et al., 2012). They also found that Blacks
had a slightly higher screening rate than Whites, Hispanics, and those
from other racial and ethnic groups. A previous HFHS study also found
that those who were older, Black, or married were more likely to be
screened for CRC (Shires et al., 2011). While previous population-based
studies have found that having higher education and income levels are
associated with CRC screening (Coleman King et al., 2012; Klabune
et al., 2013; Shapiro et al., 2012; Joseph et al., 2012), our study did not
ﬁnd a signiﬁcant difference in screening by educational level or income.
Our analyses found no signiﬁcant differences in mammography use
or Pap testing between women with and without a family history of
breast cancer and cervical cancer respectively. Consistent with previous
research (Townsend et al., 2013; Zlot et al., 2012; Bostean et al., 2013;
Ponce et al., 2012), we did see a signiﬁcant higher use of CRC screening
tests among women with a family history of CRC. While our results on
mammography and family history of breast cancer are inconsistent
with previous results (Townsend et al., 2013; Zlot et al., 2012; Bostean
et al., 2013; Ponce et al., 2012), the lack of association between Pap test-
ing and family history of cervical cancer is consistent with previous re-
search (Bellinger et al., 2013). Highlighting a family history of cancer
can provide a particularly salient entry point in patient-provider discus-
sions of the importance of cancer screening, particularly CRC screening.
A personal history of cancer, or being a cancer survivor, was associated
with CRC screening, but not breast or cervical cancer screening. These
results are in contrast with a recentmeta-analysis that found that over-
all, cancer survivors were more likely to receive cancer screening, and
speciﬁcally more likely to be screened for breast cancer, cervical cancer,
and CRC when compared to non-cancer controls (Corkum et al., 2013).
Studies of cancer screening have highlighted disparities based on
race, ethnicity, income, education, health insurance status, and other
socio-economic factors (Coleman King et al., 2012; Klabune et al.,
2013; Swan et al., 2010; Miller et al., 2012; Shapiro et al., 2012;
Rauscher et al., 2012; Berry et al., 2009). Our results indicate that even
in an insured population with access to health care, some of these dis-
parities persist and vary by screening test. While reforms in health
care might lead to a greater number of insured individuals and presum-
ably increased rates of cancer screening, members of medically under-
served groups and those with less education and income might still be
screened at lower rates (Shi et al., 2011; Stimpson et al., 2012;
Doubeni et al., 2012).
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collection, including self-report of screenings and family cancer history.
However, other studies at HFHS on cancer screening have used claims
data to assess utilization and have similarly high proportions of patients
being screened (Shires et al., 2011; Lafata et al., 2005). Patients within
HFHS tend to remain in the system for long periods of time (average
length 7.5 years, unpublished data), which suggests a strong relation-
ship with HFHS as a medical home. This attribute of HFHS patients
was not measured in the current study, but might have contributed to
the high screening prevalence found in our study. Of course, given the
unique characteristics of patients within HFHS and the system itself,
our results are not generalizable to a general population of insured or
uninsured.
Participating in a health maintenance organization addresses many
of the facilitators and barriers associated with cancer screening, includ-
ing provider recommendations for screening, continuity with a primary
care provider, comprehensive service delivery, strong afﬁliation with a
medical home, and screening reminder systems (Alexandraki and
Mooradian, 2010; O'Malley et al., 2002; Sabatino et al., 2012). To im-
prove cancer screening uptake among its enrollees, HFHS sends out pa-
tient reminders for screening in annual birthday cards. Given that the
Community Guide (U.S. Preventive Services Task Force (USPSTF),
2011) has found patient reminders to be an effective strategy to in-
crease uptake of breast, cervical and CRC screening, screening rates at
HFHS might be somewhat higher than expected from insured popula-
tions that are not exposed to additional interventions. Furthermore,
other intrapersonal and structural barriers—such as lack of transporta-
tion or sick leave, personal beliefs and attitudes towards screening, or
language and cultural barriers (Alexandraki and Mooradian, 2010;
Schueler et al., 2008; Del Carmen and Avila-Wallace, 2013)—might
still impede cancer screening, even among an insured population, and
will require novel interventions to address appropriately. Further re-
search on cancer screening among insured populations should focus
on better understanding the facilitators and barriers to cancer screening
to informwhat types of interventionsmight be best suited to thosewho
are insured, yet are non-routinely, rarely, or never screened. Neverthe-
less, the results of this study hold promise that Healthy People 2020
cancer screening objectives might be obtainable once access to health
care insurance among US residents is expanded.
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